OriGene Technologies Inc. has announced that they have entered into an agreement with Cytomyx Holdings, PLC to co-develop tools to profile gene expression and biomarker validation in a range of human cancers.
Under the terms of the agreement, Cytomyx will supply hundreds of characterized RNA samples from a wide range of major cancers from its extensive Biorepository.
OriGene will use these samples to develop generations of their existing Rapid-Scan Gene Expression Panel product line.
The Rapid-Scan panels will enable researchers to profile gene expression levels in these patient derived samples to determine linkages between gene expression and tumor occurrence and development.
Cytomyx also intends to develop complementary tissue microarrays (TMAs), which can be used to further investigate these linkages at the protein expression level using immunohistochemistry.
“The development of this new high-throughput analysis system will enable researchers to rapidly assess gene expression levels across a wide range of patients with different forms and stages of the major cancers,” said Mike Kerins, CEO of Cytomyx.
“As such we expect that it will become an important new resource in the effort to characterize tumors at the genetic level and may help in the development of precisely targeted new diagnostics and therapies in the future.”
“We are pleased to be working with OriGene who have established themselves as a leading developer of genetic research products.”
“In particular their access to the global market for research products will help to ensure the success of this important new product line.”
“Having a tool that demonstrates correlation of mRNA levels to detailed disease stages is critical for biomarker validation,” said Rich Hamer, PhD, VP Business Development at OriGene.
“OriGene's Rapid-Scan platform combined with the depth of Cytomyx' Biorepository greatly enhances the target screening and biomarker validation toolset needed by today's researchers.”